



Malaysia, 2015

Global Vaccine Action Plan (GVAP) and Regional framework indicators

Polio-free status sustained	Yes	At least one dose of IPV introduced by end of 2015	Yes
Country achieved MNT elimination	Yes	Increasing trend in domestic expenditure since 2010	Yes
Country verified for measles elimination	No	NITAG established (with administrative/legal basis only)	Yes
Seroprevalence of chronic hepatitis B infection (HBsAg) reduced to < 1% in 5 year olds by 2017	Yes	Functional NITAG (legal basis, TORs, ≥ 5 areas of expertise, ≥ 1 meeting per year, agenda and background docs, disclosure of conflict of interest)	Yes
At least one new or underutilized vaccine introduced since 2010*	Yes (Men ACWY)	JE vaccine introduced in JE risk areas	Yes
DTP3 national immunization coverage ≥ 95% by 2020	99%	Primary series JE vaccine ≥ 90% coverage among children under 15 years old	92.6%
DTP3 coverage ≥ 90% in at least 90% of districts (proportion of districts with ≥ 90% coverage)	No (71.8%)	Case-based surveillance for invasive bacterial vaccine-preventable disease	No
Sustained DTP3 coverage ≥ 95% for three or more years	Yes	Case-based surveillance for rotavirus disease	No
DTP dropout rate < 5%	-4.65%	Rubella and CRS case-based data submitted to WPRO	Rubella only

* New or underutilized vaccines include Hib, HPV, PCV and RV. IPV and JE are not counted. Otherwise, "Yes (specified)" is indicated to account for other vaccines.

Population		
	JRF	UN*
Total	30 485 200	30 331 007
Births	511 865	509 070
NIP target < 1 year (surviving infants)	511 865	499 516
Source of data for NIP target	Census data	

* United Nations World Population Prospects: The 2015 Revision

Finance	
Gross national income per capita* (US \$)	\$ 10 570
Line item in budget for vaccines	Yes
% of vaccines in routine immunization funded by government	
% of routine immunization - funded by government	
Eligible for GAVI support	No

* World Bank Open Data

Reported cases of selected vaccine preventable diseases


Year	Acute flaccid paralysis (AFP)		Measles		Rubella		Congenital rubella syndrome (CRS)		Neonatal tetanus		Total tetanus		Diphtheria		Pertussis	
	Non-polio AFP rate	% adequate specimens	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR
2011	1.4	78%	1569	54.4	374	13.0			3	0.0	11	0.0	0	0.0	248	0.9
2012	1.9	94%	1868	63.7	789	26.9	1	0.0	9	0.0	34	0.1	0	0.0	217	0.7
2013	2.0	83%	195	6.6	1138	38.3	4	0.0	6	0.0	32	0.1	4	0.0	222	0.7
2014	2.0	73%	221	7.3	230	7.6			8	0.0	22	0.1	2	0.0	500	1.7
2015	1.9	77%	1318	43.5	34	1.1			16	0.0	20	0.1	4	0.0	939	3.1

Non-polio AFP rate = incidence per 100 000 under 15 years; % adequate specimens = % of AFP cases with 2 specimens within 14 days of paralysis onset
 IR = incidence rate: for measles and rubella, per 1 000 000 population; for CRS and neonatal tetanus, per 1000 live births; for all others, per 100 000 population. Total tetanus includes neonatal tetanus cases.
 Population source: United Nations World Population Prospects


Invasive bacterial disease, rotavirus and japanese encephalitis

Year	Rotavirus diarrhea		Japanese encephalitis		Bacterial meningitis		Bacterial pneumonia	
	Surveillance system type	Confirmed cases	Surveillance system type	Confirmed cases	Surveillance system type	Confirmed cases	Surveillance system type	Confirmed cases
2013	None		Nationwide	33	None		None	
2014	None		Nationwide	68	None		None	
2015	None		Nationwide	36	None		None	

Confirmed measles cases by month of onset 2011–2015



Confirmed measles cases by age group and vaccination status, 2014–2015





Malaysia, 2015

Immunization schedule							
BCG	B	DTP-Hib-IPV	M2, M3, M5, M18	Measles	M6	OPV	Y7
DT	Y7	HepB	B, M1, M6	MR	Y7	HPV	Y13, +M6
TT	Y15	JE_liveatd	M9, M21	MMR	M12		



B=birth, W=week, M=month, Y=year

Planning	
Multi-year plan (MYP)	No
Annual workplan for immunization activities	Yes
Updated wild poliovirus importation and cVDPV response plan	Yes

NIP priority needs	
1. Management of cold chain system - e.g. replacement of old fridges	

Safe immunization	
% districts using auto-disable syringes	
System to monitor AEFI	Yes
Number of AEFI	2547
Injection safety policy implemented	Yes
Disposal methods	Incineration
Injection safety review	Yes (National)

Delivery of immunization services	
% of population served by outreach	95%
No. (%) of districts with DTP3 coverage < 80%	14 (10%)
No. (%) of districts with DTP3 coverage ≥ 90%	102 (72%)
No. (%) of districts with MCV1 coverage < 80%	28 (20%)
No. (%) of districts with MCV1 coverage ≥ 90%	76 (54%)
No. (%) of districts with DTP drop-out > 10%	
No. (%) of districts with DTP1–MCV1 drop-out > 10%	



School-based immunization	
Is there a school entry requirement?	No
If no, do schools check immunization status at enrolment?	Yes
What vaccines are required/checked?	Primary - DT, MR Secondary - HPV
At what school level/year?	
Is routine vaccination given at school?	Yes
Which vaccination?	DT, OPV, MR, HPV, TT
If yes, is this part of a comprehensive school-health program that delivers other health interventions?	Yes

Surveys		
	Coverage survey	Serosurvey
Most recent (year)		
Type		
Geographical representativeness		
Result		

Measles and rubella elimination			
Confirmed measles case rate* (per 1 million population)	43.3	Year of MCV1 introduction	1982
Confirmed rubella case rate* (per 1 million population)	0.8	Year of MCV2 introduction	2002
Discarded as non-measles rate* (Target: ≥ 2 per 100 000 population)	12.9	Year of RCV introduction	1982
% suspected cases with adequate specimens* (Target: ≥ 80%)	82.6%	Surveillance conducted for CRS	No
Imported measles cases*	2	Antigens, year and target population of last SIA	M/MMR - 2015 (0-17 yrs)
Measles cases with unknown source of infection*	516	Number vaccinated (SIA coverage)	21 518 (89%)

* Data from measles monthly country reports to WHO

Hepatitis B control			
Year HepB3 vaccine introduced nationwide	1989	Systems to deliver HepB vaccine birth dose	Hospitals, health centers, home
Year HepB birth dose introduced	1989	HBsAg results assessed for blood donors	No
HepB birth dose (within 24 hours) coverage	88%	Policy for screening of pregnant women	No
HepB birth dose (within and after 24 hours) coverage	88%	Policy to vaccinate health care workers	Yes